Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD)

Am J Vet Res. 1998 Mar;59(3):258-61.

Abstract

Objective: To determine whether the urine cortisol-to-creatinine ratio (UCCR) could replace the ACTH stimulation test in monitoring effectiveness of mitotane induction treatment in dogs with pituitary-dependent hyperadrenocorticism (PDH).

Animals: 15 dogs with PDH.

Procedure: All 15 dogs were given an induction dose of mitotane (o,p'-DDD: 35 to 50 mg/kg of body weight/d) for 3 to 14 days. During the induction period, free-catch morning urine samples were collected for determination of UCCR, followed by ACTH stimulation testing, every other day. Treatment response was divided into 3 categories: well-controlled PDH (post-ACTH serum cortisol concentration > or = 28 nmol/L but < or = 138 nmol/L), deficient cortisol secretion (post-ACTH serum cortisol concentration < 28 nmol/L), and excess cortisol secretion (post-ACTH serum cortisol concentration > 138 nmol/L).

Results: The linear relation between UCCR and post-ACTH serum cortisol concentration was significant (P < 0.001); however, the prediction intervals surrounding the line were too broad to be clinically useful. The UCCR overlapped among the 3 categories of treatment response. Nevertheless, dogs with PDH receiving mitotane induction treatment and with UCCR > 79 x 10(-6) were always classified as having excess cortisol secretion.

Conclusion and clinical relevance: The UCCR failed to predict post-ACTH cortisol concentration during mitotane induction treatment sufficiently close to be a clinically reliable indicator of treatment control. Seemingly, however, UCCR > 79 x 10(-6) obtained from a dog with PDH during mitotane induction would indicate inadequate adrenal cortex destruction and the need for continued mitotane induction; UCCR < or = 79 x 10(-6) would be inconclusive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenocortical Hyperfunction / drug therapy
  • Adrenocortical Hyperfunction / etiology
  • Adrenocortical Hyperfunction / urine
  • Adrenocortical Hyperfunction / veterinary*
  • Adrenocorticotropic Hormone
  • Animals
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers / blood
  • Biomarkers / urine
  • Creatinine / urine*
  • Dog Diseases*
  • Dogs
  • Drug Monitoring / methods
  • Drug Monitoring / veterinary
  • Female
  • Hydrocortisone / blood
  • Hydrocortisone / urine*
  • Male
  • Mitotane / therapeutic use*
  • Pituitary Diseases / drug therapy
  • Pituitary Diseases / urine
  • Pituitary Diseases / veterinary*
  • Pituitary-Adrenal Function Tests / veterinary
  • Time Factors

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers
  • Mitotane
  • Adrenocorticotropic Hormone
  • Creatinine
  • Hydrocortisone